RecruitingPhase 4NCT06445946

DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes

DECIDE: A Comparative Effectiveness Trial of Oral Metformin Versus Injectable Insulin for the Treatment of Gestational Diabetes


Sponsor

Ohio State University

Enrollment

1,572 participants

Start Date

Aug 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This is a non-inferiority patient-centered and pragmatic comparative-effectiveness pregnancy randomized controlled trial (RCT) with postpartum maternal and child follow-up through 2 years of 1,572 individuals with gestational diabetes mellitus (GDM) randomized to oral metformin versus injectable insulin. This study will determine if metformin is not inferior to insulin in reducing adverse pregnancy outcomes, is comparably safe for exposed individuals and children, and if patient-reported factors, including facilitators of and barriers to use, differ between metformin and insulin. A total of 1,572 pregnant individuals with GDM who need pharmacotherapy will be recruited at 20 U.S. sites using consistent treatment criteria to metformin versus insulin. Participants and their children will be followed through delivery to two years postpartum.


Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Insulin and a drug called Metformin for people with gestational diabetes mellitus and pregnancy, high risk. The study is currently recruiting participants at 21 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMetformin

Individuals randomized to this arm will receive oral metformin tablets for their Gestational diabetes mellitus treatment.

DRUGInsulin

Individuals randomized to this arm will receive injectable insulin for their Gestational diabetes mellitus treatment.


Locations(24)

University of Alabama

Tuscaloosa, Alabama, United States

Cedars Sinai Medical Center

Los Angeles, California, United States

University of California San Francisco

San Francisco, California, United States

Christiana Care

Newark, Delaware, United States

University of South Florida

Tampa, Florida, United States

Tufts University

Boston, Massachusetts, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Washington University in St. Louis

St Louis, Missouri, United States

University of New Mexico

Albuquerque, New Mexico, United States

Columbia University Irving Medical Center

New York, New York, United States

University of North Caroline

Chapel Hill, North Carolina, United States

Wake Forest University

Winston-Salem, North Carolina, United States

The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine

Columbus, Ohio, United States

Premier Health - Miami Valley Hospital

Dayton, Ohio, United States

Kettering Health

Kettering, Ohio, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

University of Pittsburgh

Pittsburgh, Pennsylvania, United States

Brown University

Providence, Rhode Island, United States

University of South Carolina Greenville

Greenville, South Carolina, United States

University of Texas Austin

Austin, Texas, United States

Austin Maternal Fetal Medicine

Austin, Texas, United States

University of Texas Health Science Center

Houston, Texas, United States

Eastern Virginia Medical School - Old Dominion University

Norfolk, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06445946


Related Trials